Acadia Pharmaceuticals Inc (NASDAQ: ACAD) is -8.61% lower on its value in year-to-date trading and has touched a low of $14.15 and a high of $20.68 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ACAD stock was last observed hovering at around $17.19 in the last trading session, with the day’s loss setting it -0.42%.
Currently trading at $16.77, the stock is -10.75% and -8.83% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.63 million and changing -2.44% at the moment leaves the stock 0.13% off its SMA200. ACAD registered -28.46% loss for a year compared to 6-month gain of 6.34%.
The stock witnessed a -11.18% loss in the last 1 month and extending the period to 3 months gives it a -2.95%, and is -7.25% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.44% over the week and 4.13% over the month.
Acadia Pharmaceuticals Inc (ACAD) has around 654 employees, a market worth around $2.80B and $957.80M in sales. Current P/E ratio is 12.33 and Fwd P/E is 18.05. Profit margin for the company is 23.64%. Distance from 52-week low is 18.52% and -18.91% from its 52-week high. The company has generated returns on investments over the last 12 months (29.23%).
with sales reaching $239.34M over the same period.The EPS is expected to shrink by -59.88% this year, but quarterly earnings will post 10.87% year-over-year. Quarterly sales are estimated to grow 16.28% in year-over-year returns.
The shares outstanding are 166.71M, and float is at 165.50M with Short Float at 8.70%.
The top institutional shareholder in the company is BAKER BROS. ADVISORS LP with over 42.88 million shares valued at $696.77 million. The investor’s holdings represent 25.9001 of the ACAD Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 13.71 million shares valued at $222.82 million to account for 8.3206 of the shares outstanding. The other top investors are RTW INVESTMENTS, LP which holds 13.71 million shares representing 8.2799 and valued at over $222.75 million, while BLACKROCK INC. holds 7.3194 of the shares totaling 12.06 million with a market value of $196.01 million.
Acadia Pharmaceuticals Inc (ACAD) Insider Activity
The most recent transaction is an insider sale by GAROFALO ELIZABETH A., the company’s Director. SEC filings show that GAROFALO ELIZABETH A. sold 4,919 shares of the company’s common stock on Mar 05 ’25 at a price of $18.23 per share for a total of $89673.0. Following the sale, the insider now owns 17595.0 shares.
Still, SEC filings show that on Feb 24 ’25, Kihara James (PRINCIPAL ACCOUNTING OFFICER) disposed off 475 shares at an average price of $19.96 for $9481.0. The insider now directly holds 20,228 shares of Acadia Pharmaceuticals Inc (ACAD).
